Skip to main content

Market Overview

Inovio's Pan-COVID-19 Vaccine Candidate Can Provide Immune Responses Against Variants, Animal Study Shows

Share:
Inovio's Pan-COVID-19 Vaccine Candidate Can Provide Immune Responses Against Variants, Animal Study Shows
  • Inovio Pharmaceuticals Inc (NASDAQ: INOhas announced results from a preclinical study of its next-generation Pan-COVID-19 vaccine candidate, INO-4802, that demonstrates its potential to induce cross-reactive immune responses against current and emerging viral variants.
  • Data showed the vaccine candidate induced potent neutralizing antibodies and T cell responses against the original Wuhan strain as well as against B.1.1.7 (U.K. variant), B.1.351 (South African variant), and P.1. (Brazilian variant) in preclinical models.
  • INO-4802 has potential as either a first-line vaccine or a boost for individuals previously immunized with various Wuhan-matched vaccines.
  • The company plans to conduct Phase 1/2 trials this year with INO-4802.
  • Earlier this week, the company announced positive data from the Phase 2 segment of its Phase 2/3 INNOVATE trial in the U.S., evaluating INO-4800, its DNA vaccine candidate for COVID-19.
  • INO-4800 will enter a global Phase 3 trial this summer.
  • Price Action: INO shares are trading 0.15% higher at $6.5 on the last check Wednesday.
 

Related Articles (INO)

View Comments and Join the Discussion!

Posted-In: Briefs COVID-19 VaccineBiotech News Health Care Small Cap FDA General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com